Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 11/2017

01-11-2017 | Original Article

Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies

Authors: Margrethe Raspotnig, Mette Haugen, Maria Thorsteinsdottir, Ingunn Stefansson, Helga B. Salvesen, Anette Storstein, Christian A. Vedeler

Published in: Cancer Immunology, Immunotherapy | Issue 11/2017

Login to get access

Abstract

Background

Cerebellar degeneration-related protein 2 (CDR2) has been presumed to be the main antigen for the onconeural antibody Yo, which is strongly associated with ovarian cancer and paraneoplastic cerebellar degeneration (PCD). Recent data show that Yo antibodies also target the CDR2-like protein (CDR2L). We, therefore, examined the expression of CDR2 and CDR2L in ovarian cancer tissue from patients with and without Yo antibodies and from various other cancerous and normal human tissues.

Methods

Ovarian cancer tissue and serum samples from 16 patients were included in the study (four with anti-Yo and PCD, two with anti-Yo without PCD, five with only CDR2L antibodies, and five without onconeural antibodies). Clinical data were available for all patients. The human tissues were examined by western blot and immunohistochemistry using rabbit CDR2 and CDR2L antibodies.

Results

Ovarian cancers from all 16 patients expressed CDR2 and CDR2L proteins. Both proteins were also present in normal and cancer tissue from mammary tissue, kidney, ovary, prostate, and testis.

Conclusion

CDR2L is present in ovarian cancers from patients with and without Yo antibodies as was shown previously for CDR2. In addition, both CDR2 and CDR2L proteins are more widely expressed than previously thought, both in normal and cancerous tissues.
Literature
1.
Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349(16):1543–1554CrossRefPubMed
2.
Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G et al (2010) Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 67(3):330–335CrossRefPubMed
3.
Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F et al (2011) Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 18(1):19CrossRefPubMed
4.
Monstad SE, Storstein A, Dorum A, Knudsen A, Lonning PE, Salvesen HB et al (2006) Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 144(1):53–58CrossRefPubMedPubMedCentral
5.
Peterson K, Rosenblum MK, Kotanides H, Posner JB (1992) Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 42(10):1931–1937CrossRefPubMed
6.
Dropcho EJ, Chen YT, Posner JB, Old LJ (1987) Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 84(13):4552–4556CrossRefPubMedPubMedCentral
7.
Fathallah-Shaykh H, Wolf S, Wong E, Posner JB, Furneaux HM (1991) Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 88(8):3451–3454CrossRefPubMedPubMedCentral
8.
Fathallah-Shaykh H, Finizio J, Posner JB (1992) Yo sera recognize a family of DNA binding proteins. Neurology 42(Suppl 3):415 (abstract)
9.
Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB (1997) A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci 17(4):1406–1415PubMed
10.
Eichler TW, Totland C, Haugen M, Qvale TH, Mazengia K, Storstein A et al (2013) CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLoS ONE 8(6):e66002CrossRefPubMedPubMedCentral
11.
Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA (2014) Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol 128(6):835–852CrossRefPubMedPubMedCentral
12.
Hwang JY, Lee J, Oh CK, Kang HW, Hwang IY, Um JW et al (2016) Proteolytic degradation and potential role of onconeural protein CDR2 in neurodegeneration. Cell Death Dis 7(6):e2240CrossRefPubMedPubMedCentral
13.
Totland C, Aarskog NK, Eichler TW, Haugen M, Nostbakken JK, Monstad SE et al (2011) CDR2 antigen and Yo antibodies. Cancer Immunol Immunother 60(2):283–289CrossRefPubMed
14.
Monstad SE, Knudsen A, Salvesen HB, Aarseth JH, Vedeler CA (2009) Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother 58(11):1795–1800CrossRefPubMed
15.
Storstein A, Monstad SE, Haugen M, Mazengia K, Veltman D, Lohndal E et al (2011) Onconeural antibodies: improved detection and clinical correlations. J Neuroimmunol 232(1–2):166–170CrossRefPubMed
16.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds) (2014) WHO classification of tumours of female reproductive organs, 4th edn. WHO Press, Geneva
17.
Prat J (2014) Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1–5CrossRefPubMed
18.
Furneaux HM, Rosenblum MK, Dalmau J, Wong E, Woodruff P, Graus F et al (1990) Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 322(26):1844–1851CrossRefPubMed
19.
Darnell JC, Albert ML, Darnell RB (2000) Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res 60(8):2136–2139PubMed
20.
Balamurugan K, Luu VD, Kaufmann MR, Hofmann VS, Boysen G, Barth S et al (2009) Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response. Oncogene 28(37):3274–3285CrossRefPubMed
21.
O’Donovan KJ, Diedler J, Couture GC, Fak JJ, Darnell RB (2010) The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells. PLoS ONE 5(4):e10045CrossRefPubMedPubMedCentral
22.
Matschke J, Kromminga A, Erbersdobler A, Lamszus K, Anders S, Kofuncu E (2007) Paraneoplastic cerebellar degeneration and anti-Yo antibodies in a man with prostatic adenocarcinoma. J Neurol Neurosurg Psychiatry 78(7):775–777CrossRefPubMed
23.
Rosine N, Chretien P, Adam C, Beaudonnet G, Not A, Drai J et al (2017) Expression of Yo antigen in a prostatic adenocarcinoma. Can J Neurol Sci 44(2):221–223CrossRefPubMed
24.
Storstein A, Raspotnig M, Vitaliani R, Giometto B, Graus F, Grisold W et al (2016) Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes. J Neurol 263(5):1001–1007CrossRefPubMed
25.
Coronella-Wood JA, Hersh EM (2003) Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 52(12):715–738CrossRefPubMed
26.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998CrossRefPubMed
27.
Albert ML, Darnell RB (2004) Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 4(1):36–44CrossRefPubMed
28.
de Graaf MT, de Beukelaar JW, Haasnoot GW, Levering WH, Rogemond V, Didelot A et al (2010) HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. J Neuroimmunol 226(1–2):147–149CrossRefPubMed
29.
Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N (2000) Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191(3):423–434CrossRefPubMedPubMedCentral
30.
Yshii LM, Gebauer CM, Pignolet B, Mauré E, Quériault C, Pierau M et al (2016) CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain 139(11):2923–2934CrossRef
31.
Blachere NE, Orange DE, Santomasso BD, Doerner J, Foo PK, Herre M et al (2014) T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. Eur J Immunol 44(11):3240–3251CrossRefPubMedPubMedCentral
32.
Calzascia T, Loh JM, Di Berardino-Besson W, Masson F, Guillaume P, Burkhardt K et al (2008) Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes. Glia. 56(15):1625–1636CrossRefPubMed
33.
34.
35.
Monstad SE, Vedeler CA (2006) An immunoprecipitation assay for the detection of onconeural antibodies. Acta Neurol Scand Suppl 183:71–72CrossRefPubMed
36.
Storstein A, Monstad SE, Nakkestad HL, Husebye ES, Vedeler CA (2004) Paraneoplastic antibodies against HuD detected by a sensitive radiobinding assay. J Neurol 251(2):197–203CrossRefPubMed
Metadata
Title
Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies
Authors
Margrethe Raspotnig
Mette Haugen
Maria Thorsteinsdottir
Ingunn Stefansson
Helga B. Salvesen
Anette Storstein
Christian A. Vedeler
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 11/2017
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-017-2041-8

Other articles of this Issue 11/2017

Cancer Immunology, Immunotherapy 11/2017 Go to the issue

Original Article

Autoimmune diabetes induced by PD-1 inhibitor—retrospective analysis and pathogenesis: a case report and literature review

Original Article

IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model

Review

Therapeutic antibodies against cancer stem cells: a promising approach

Original Article

CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases

Letter to the Editors

CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target

Original Article

Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits